Protalix Biotherapeutics Inc (PLX) — Capital Reinvestment Ratio
Protalix Biotherapeutics Inc (PLX) has a Capital Reinvestment Ratio of 0.61x as of December 2025, meaning it reinvests 1% of its operating cash flow ($2.03 Million) in capital expenditures ($1.24 Million). See PLX net asset quality score to measure how much of total assets are equity-financed.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Protalix Biotherapeutics Inc Capital Reinvestment Ratio (2009–2024)
This chart tracks Protalix Biotherapeutics Inc's Capital Reinvestment Ratio across 3 annual periods. Check PLX cash reinvestment to operating cash ratio to assess the company's total reinvestment commitment from operating cash flow.
Annual Capital Reinvestment Ratio for Protalix Biotherapeutics Inc (2009–2024)
Year-by-year Capital Reinvestment Ratio for Protalix Biotherapeutics Inc from 2009 to 2024. For live market cap and broader valuation context, see Protalix Biotherapeutics Inc market cap and net worth.
| Year | Reinvestment Ratio | Operating CF (USD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2024 | 0.15x | $8.67 Million | $1.28 Million | ▼ -95.5% |
| 2012 | 3.26x | $635.00K | $2.07 Million | ▲ +2236.8% |
| 2009 | 0.14x | $44.45 Million | $6.20 Million | — |